281 related articles for article (PubMed ID: 28247011)
1. Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
Mittapalli RK; Nuthalapati S; Shepherd SP; Xiong H
Cancer Chemother Pharmacol; 2017 Mar; 79(3):587-594. PubMed ID: 28247011
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML
Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279
[TBL] [Abstract][Full Text] [Related]
3. Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
Niu J; Scheuerell C; Mehrotra S; Karan S; Puhalla S; Kiesel BF; Ji J; Chu E; Gopalakrishnan M; Ivaturi V; Gobburu J; Beumer JH
J Clin Pharmacol; 2017 Aug; 57(8):977-987. PubMed ID: 28387939
[TBL] [Abstract][Full Text] [Related]
4. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Škapa P; Dundr P
Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
[TBL] [Abstract][Full Text] [Related]
5. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
[TBL] [Abstract][Full Text] [Related]
6. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Coleman RL; Sill MW; Bell-McGuinn K; Aghajanian C; Gray HJ; Tewari KS; Rubin SC; Rutherford TJ; Chan JK; Chen A; Swisher EM
Gynecol Oncol; 2015 Jun; 137(3):386-91. PubMed ID: 25818403
[TBL] [Abstract][Full Text] [Related]
7. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
[TBL] [Abstract][Full Text] [Related]
8. A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Bell-McGuinn KM; Konner JA; Tew WP; Hensley ML; Iasonos A; Charpentier E; Mironov S; Sabbatini P; Aghajanian C
Int J Gynecol Cancer; 2016 Feb; 26(2):255-60. PubMed ID: 26745694
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
Lertkhachonsuk AA; Suprasert P; Manchana T; Kittisiam T; Kantathavorn N; Chansoon T; Khunamornpong S; Pohthipornthawat N; Tangjitgamol S; Luasiripanthu T; Teerapakpinyo C; Shuangshot S; Iemwimangsa N; Chantratita W
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2381-2388. PubMed ID: 32856869
[TBL] [Abstract][Full Text] [Related]
10. A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients.
Stodtmann S; Nuthalapati S; Eckert D; Kasichayanula S; Joshi R; Bach BA; Mensing S; Menon R; Xiong H
J Clin Pharmacol; 2021 Sep; 61(9):1195-1205. PubMed ID: 33894017
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies.
Salem AH; Giranda VL; Mostafa NM
Clin Pharmacokinet; 2014 May; 53(5):479-88. PubMed ID: 24452810
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR.
Sharma S; Mittapalli RK; Holen KD; Xiong H
Clin Pharmacokinet; 2015 Oct; 54(10):1071-81. PubMed ID: 25761639
[TBL] [Abstract][Full Text] [Related]
13. Disparities between Uptake of Germline
Hur YM; Mun J; Kim MK; Lee M; Kim YH; Kim SC
J Korean Med Sci; 2021 Oct; 36(38):e241. PubMed ID: 34609091
[TBL] [Abstract][Full Text] [Related]
14. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline
Kristeleit R; Shapiro GI; Burris HA; Oza AM; LoRusso P; Patel MR; Domchek SM; Balmaña J; Drew Y; Chen LM; Safra T; Montes A; Giordano H; Maloney L; Goble S; Isaacson J; Xiao J; Borrow J; Rolfe L; Shapira-Frommer R
Clin Cancer Res; 2017 Aug; 23(15):4095-4106. PubMed ID: 28264872
[No Abstract] [Full Text] [Related]
15. Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies.
Mehrotra S; Gopalakrishnan M; Gobburu J; Greer JM; Piekarz R; Karp JE; Pratz K; Rudek MA
Br J Clin Pharmacol; 2017 Aug; 83(8):1688-1700. PubMed ID: 28156017
[TBL] [Abstract][Full Text] [Related]
16. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
[TBL] [Abstract][Full Text] [Related]
17. [Not Available].
Gladieff L; Lyonnet DS; Lortholary A; Leary A; Genestie C; Ray-Coquard I
Bull Cancer; 2017 May; 104 Suppl 1():S16-S23. PubMed ID: 28625311
[TBL] [Abstract][Full Text] [Related]
18. Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
Somasegar S; Weiss AS; Norquist BM; Khasnavis N; Radke M; Manhardt E; Pennil C; Pennington KP; Eckert MA; Chryplewicz A; Lengyel E; Swisher EM
Gynecol Oncol; 2021 Oct; 163(1):130-133. PubMed ID: 34452747
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Han K; Jin JY; Marchand M; Eppler S; Choong N; Hack SP; Tikoo N; Bruno R; Dresser M; Musib L; Budha NR
Cancer Chemother Pharmacol; 2015 Nov; 76(5):917-24. PubMed ID: 26365290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
